# Surface Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/surface-oncology

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.surfaceoncology.com
- Total disclosed funding: $24M
- Latest round: Series A (Jan 9, 2015)
- Investors on record: 6

## About

Surface Oncology, Inc. focuses on developing innovative cancer immunotherapies aimed at enhancing the body's immune response to cancers, particularly through the exploration of novel therapeutic targets.Founded in 2014 and headquartered in Cambridge, US, Surface Oncology, Inc. specializes in advancing immunotherapy solutions for cancer treatment. John Stagg is the founder, and the company has engaged in seven deals to date. The most recent significant transaction occurred on April 18, 2018, when the company completed an ADD-ON, Trade Sale funding round led by Coherus Biosciences, Inc., raising USD 40.00 mn. The total amount raised by the company stands at USD 11.50 mn.Surface Oncology, Inc. develops a range of cancer immunotherapies designed to harness the body's immune system to combat tumors. Their product offerings include targeted therapies that focus on enhancing immune checkpoint responses, aimed at providing treatment options for various cancer types. The company’s innovations cater primarily to oncology specialists and healthcare providers, facilitating improved patient care in cancer treatment, with a market presence extending across North America and Europe.In 2022, Surface Oncology, Inc. reported a revenue of USD 30.00 mn with an EBITDA of USD -60.36 mn, reflecting the financial dynamics typical for companies in clinical development stages.Looking ahead, Surface Oncology, Inc. aims to expand its product line by developing new immunotherapy treatments scheduled for launch in the coming years. The company is targeting expansion into additional markets in Europe and Asia by 2025. The funding raised during the latest round will support these initiatives, facilitating the advancement of their therapeutic pipeline and enhancing operational capabilities.

## Funding rounds

- Series A, Jan 9, 2015, $24M — Atlas Venture, New Enterprise Associates, Lilly Ventures, Amgen Ventures, F-Prime Capital, Novartis Institute for Biomedical Research
- Seed, Jun 1, 2014 — Atlas Venture

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed, Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Novartis Institute for Biomedical Research — Series A